CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 122 filers reported holding CRINETICS PHARMACEUTICALS IN in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $47,088,204 | +67.8% | 1,583,329 | +1.7% | 4.47% | +103.4% |
| Q2 2023 | $28,061,140 | +7.9% | 1,557,222 | -3.8% | 2.20% | -6.1% |
| Q1 2023 | $26,003,148 | +6.9% | 1,619,125 | +21.8% | 2.34% | +3.7% |
| Q4 2022 | $24,326,428 | -8.0% | 1,329,313 | -1.3% | 2.26% | -15.7% |
| Q3 2022 | $26,448,000 | +14.3% | 1,346,652 | +8.5% | 2.68% | -0.6% |
| Q2 2022 | $23,137,000 | +80.9% | 1,240,609 | +112.9% | 2.69% | +138.7% |
| Q1 2022 | $12,792,000 | +65.1% | 582,767 | +113.6% | 1.13% | +103.2% |
| Q4 2021 | $7,750,000 | – | 272,796 | – | 0.56% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 2,030,616 | $31,028,000 | 6.04% |
| 5AM Venture Management, LLC | 1,362,286 | $20,816,000 | 3.75% |
| Burrage Capital Management LLC | 272,393 | $4,162,000 | 3.37% |
| Altium Capital Management LP | 361,930 | $5,530,000 | 1.54% |
| Vivo Capital, LLC | 2,214,138 | $33,832,000 | 1.19% |
| Bain Capital Life Sciences Investors, LLC | 1,071,428 | $16,371,000 | 0.93% |
| Perceptive Advisors | 3,659,381 | $51,606,000 | 0.65% |
| New Leaf Venture Partners, L.L.C. | 141,000 | $2,154,000 | 0.50% |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 2,003,688 | $30,616,000 | 0.45% |
| Opaleye Management Inc. | 188,000 | $2,873,000 | 0.42% |